Delivery Order SPE2DB20D9332-SPE2DB25FV3A0

Award Date 1/15/25
Potential Completion Date 2/6/25
Potential Value $9.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $9,284.40 firm fixed-price contract is for the delivery of XOLAIR 150 MG/ML syringes, a specialized pharmaceutical product, with a period of performance through March 5, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,547.40 contract is for the delivery of XOLAIR 150 MG/ML SYRINGE medication, with a completion date of January 30, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
This firm fixed-price delivery order contract was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $3,094.80 and has a completion date of June 20, 2024. It is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. This award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $18,568.80, is for the supply of XOLAIR 150 MG/ML syringes. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price delivery orders for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $37,137.60, is for the delivery of XOLAIR 150 MG/ML syringes to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,160.55, is for the delivery of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, with a period of performance through May 14, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $9,284.40 contract is for the delivery of Xolair 150 mg/mL syringes and has a period of performance through November 29, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,868.50 contract is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a specialty pharmaceutical product, with a period of performance through August 16, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,481.65 firm fixed-price contract is for the supply of XOLAIR 150 MG/ML SYRINGE, with a period of performance through September 13, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,094.80 contract is for the delivery of Xolair 150 mg/mL syringes to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
  • SPE2DB20D9332
    Indefinite Delivery Contract
  • SPE2DB20D9332-SPE2DB25FV3A0
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $9,284.40, is for the delivery of XOLAIR 150 MG/ML syringes. The award has an ultimate completion date of February 6, 2025.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables.

Generated 4/17/25, 8:44 AM